Tarsus Pharmaceuticals (TARS) EBT (2020 - 2025)
Historic EBT for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$12.7 million.
- Tarsus Pharmaceuticals' EBT rose 4599.99% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.0 million, marking a year-over-year increase of 3899.41%. This contributed to the annual value of -$115.6 million for FY2024, which is 1496.69% up from last year.
- Per Tarsus Pharmaceuticals' latest filing, its EBT stood at -$12.7 million for Q3 2025, which was up 4599.99% from -$20.2 million recorded in Q2 2025.
- In the past 5 years, Tarsus Pharmaceuticals' EBT registered a high of $10.7 million during Q1 2021, and its lowest value of -$42.5 million during Q4 2023.
- For the 5-year period, Tarsus Pharmaceuticals' EBT averaged around -$20.1 million, with its median value being -$22.5 million (2022).
- Its EBT has fluctuated over the past 5 years, first soared by 64793.05% in 2021, then plummeted by 47411.81% in 2023.
- Quarter analysis of 5 years shows Tarsus Pharmaceuticals' EBT stood at -$14.4 million in 2021, then rose by 5.61% to -$13.6 million in 2022, then plummeted by 211.62% to -$42.5 million in 2023, then skyrocketed by 45.63% to -$23.1 million in 2024, then skyrocketed by 45.06% to -$12.7 million in 2025.
- Its EBT was -$12.7 million in Q3 2025, compared to -$20.2 million in Q2 2025 and -$25.0 million in Q1 2025.